{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:58:22Z","timestamp":1794016702399,"version":"4.8.0"},"reference-count":28,"publisher":"Academy of Managed Care Pharmacy","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.18553\/jmcp.2026.32.8.903","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:41:00Z","timestamp":1785148860000},"page":"903-910","source":"Crossref","is-referenced-by-count":2,"title":["Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey"],"prefix":"10.18553","volume":"32","author":[{"given":"Michael J.","family":"DiStefano","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora"},{"name":"Center for Bioethics and Humanities, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Zon","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik G.","family":"Olson","sequence":"additional","affiliation":[{"name":"Ipsos, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard F.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD"},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"r1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142026.\n                      Diabetes Care\n                      . 2026;49(suppl 1):S183-S215. doi:10.2337\/dc26-S009","DOI":"10.2337\/dc26-S009"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S010"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S011"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000047994"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S277676"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002517"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23952"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2026.32.3.281"},{"key":"r11","unstructured":"U.S. Food & Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. Accessed April 27. 2026. https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2026.32.3.271"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1080\/20523211.2024.2441220"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70227"},{"key":"r15","unstructured":"Tirrell M. The end of a shortage of popular weight-loss drugs may mean many people lose access to them. CNN. Published online 2024. Accessed July 28, 2025. https:\/\/www.cnn.com\/2024\/10\/09\/health\/tirzepatide-compounded-weight-loss-drugs\/index.html"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1093\/poq\/nfq048"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.29115\/SP-2009-0019"},{"key":"r18","unstructured":"U.S. Census Bureau. American Community Survey Data. Accessed August 28, 2025. https:\/\/www.census.gov\/programs-surveys\/acs"},{"key":"r19","volume-title":"Survey Sampling","author":"Kish L","year":"1965"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-06737-1"},{"key":"r21","unstructured":"U.S. Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. March 3, 2026. Accessed March 11, 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s"},{"key":"r22","unstructured":"Wosinska ME. The Wild East of Semaglutide. Brookings. April 21, 2025. Accessed August 18, 2025. https:\/\/www.brookings.edu\/articles\/the-wild-east-of-semaglutide\/"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.7.953"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103680"},{"key":"r25","unstructured":"Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027. November 2025. Accessed April 27, 2026. https:\/\/www.cms.gov\/files\/document\/fact-sheet-negotiated-prices-ipay-2027.pdf"},{"key":"r26","unstructured":"The White House. Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients. November 6, 2025. Accessed April 27, 2026. https:\/\/www.whitehouse.gov\/fact-sheets\/2025\/12\/fact-sheet-president-donald-j-trump-announces-largest-developments-to-date-in-bringing-most-favored-nation-pricing-to-american-patients\/"},{"key":"r27","unstructured":"U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. April 1, 2026. Accessed April 27, 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01473-y"}],"container-title":["Journal of Managed Care &amp; Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:41:23Z","timestamp":1785148883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.8.903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.18553\/jmcp.2026.32.8.903"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.8.903","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}